News & Updates

Show Multimedia Only

Inherited risk predicts increases in fibrosis in MASLD patients

Genetic risk score (GRS), polygenic risk score-hepatic fat content (PRS-HFC), its adjusted version (PRS-5), and PNPLA3 genotypes alone show a significant relationship with increased fibrosis severity per decade in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), reports a study.

Inherited risk predicts increases in fibrosis in MASLD patients

7 hours ago

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

08 Oct 2025

Adding liver-directed radiation therapy (RT) to atezolizumab and bevacizumab (A/B) produces limited additional toxicity with higher response rates among patients with hepatocellular carcinoma (HCC), reports a recent study. However, substantial differences in baseline characteristics hinder a full interpretation of this data.

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

08 Oct 2025

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

02 Oct 2025

The use of direct oral anticoagulants (DOACs) appears to be safer than warfarin for patients with nonvalvular atrial fibrillation (AF) and liver cirrhosis (LC), suggests a study. This is particularly true to reducing the risk of major bleeding in those with Child-Pugh class A disease.

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

02 Oct 2025

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

24 Sep 2025

Metabolic dysfunction–associated steatotic liver disease (MASLD) can lead to the development of metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma (HCC). Hong Kong studies show that sodium-glucose cotransporter 2 inhibitors (SGLT2i), such as empagliflozin, can reduce liver fat in nondiabetic patients with MASLD and lower the risk of HCC in patients with coexisting type 2 diabetes (T2D) and chronic hepatitis B (CHB).

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

24 Sep 2025

Clinical research in non-university public hospitals correlated with improved patient outcomes

19 Sep 2025 by

More than 10 percent of full-time clinicians in Hong Kong’s non-university public hospitals engaged in original research as principal investigators (PIs), contributing to nearly one-third of the city’s peer-reviewed studies published in 2016–2021. Their clinical research activity is correlated with improved patient outcomes.

Clinical research in non-university public hospitals correlated with improved patient outcomes

19 Sep 2025

LTSG delivers durable weight loss, improves metabolic syndrome

18 Sep 2025

Simultaneous liver transplantation (LT) and sleeve gastrectomy (SG) is effective in sustaining weight loss, managing diabetes and hypertension, and preventing recurrence of steatosis and possibly fibrosis compared with LT alone, suggests a study.

LTSG delivers durable weight loss, improves metabolic syndrome

18 Sep 2025

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

18 Sep 2025 by

Many patients with cirrhosis and acute kidney injury (AKI) need 2 days to show response to albumin treatment, a study has found. Therefore, reducing the duration of albumin therapy may result in overtreatment with terlipressin.

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

18 Sep 2025

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

18 Sep 2025

The addition of pembrolizumab to the combination of gemcitabine and cisplatin does not appear to worsen the health-related quality of life (HRQoL) in patients with advanced biliary tract cancer (BTC), results of the phase III KEYNOTE-966 study have shown.

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

18 Sep 2025

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

12 Sep 2025 by

Findings from the TALENTACE trial presented at ESMO GI 2025 support the combination of atezolizumab and bevacizumab after transarterial chemoembolization (TACE) for the treatment of individuals with systemically untreated, intermediate-to-high tumour burden, unresectable hepatocellular carcinoma (HCC).

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

12 Sep 2025

Liver-related events, cardiovascular outcomes elevated in steatotic liver disease patients

11 Sep 2025

Individuals with steatotic liver disease are at an increased risk of developing liver-related events, liver cancer, and cardiovascular outcomes, reveals a study.

Liver-related events, cardiovascular outcomes elevated in steatotic liver disease patients

11 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Inherited risk predicts increases in fibrosis in MASLD patients

Inherited risk predicts increases in fibrosis in MASLD patients

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

Clinical research in non-university public hospitals correlated with improved patient outcomes

Clinical research in non-university public hospitals correlated with improved patient outcomes

LTSG delivers durable weight loss, improves metabolic syndrome

LTSG delivers durable weight loss, improves metabolic syndrome

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

Patients with cirrhosis, AKI may require 48 h to respond to albumin therapy

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

Gemcitabine-cisplatin plus pembrolizumab combo feasible in advanced BTC

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

TALENTACE supports atezolizumab + bevacizumab after TACE for HCC

Liver-related events, cardiovascular outcomes elevated in steatotic liver disease patients

Liver-related events, cardiovascular outcomes elevated in steatotic liver disease patients